Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects.
What is known and objective: Teneligliptin is a DPP‐4 inhibitor used for the treatment of type 2 diabetes mellitus, commonly prescribed in combination with glimepiride. Teneligliptin is metabolized by CYP3A4, and glimepiride might be partly metabolized by CYP3A4. The aim of the study was to investig...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 44; no. 5; pp. 720 - 726 |
|---|---|
| Autores principales: | , , , , |
| Formato: | clinical trial research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Oct2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |